The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.
Vaccine NFU1 (S-L+) MRC was prepared by high multiplicity infection of serum-deprived human embryonic lung (MRC 5) cells with type 1 Herpes simplex virus. The preparative process removed inoculum virus particles and virus DNA while virus particle and DNA synthesis was inhibited by the presence of lithium chloride in the cell culture medium. The vaccine stimulated neutralising antibody in vaccinated mice and provided long-term protection against intra-vaginal challenge with type 2 herpes virus. The safety of the vaccine was confirmed by inoculation into newborn mice and cell lines of human, mammalian, and rodent origin. There was no evidence of cell transformation in vitro or of oncogenicity or teratogenicity in rodent species. It is intended to investigate the efficiency of this vaccine in human subjects.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000276:immunology; D002460:Cell Line; D006224:Cricetinae; D006561:Herpes Simplex / Q000517:prevention & control*; D006801:Humans; D007668:Kidney; D008168:Lung; D009500:Neutralization Tests; D012449:Safety; D018139:Simplexvirus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000592:standards
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines